BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsilimigras DI, Bagante F, Moris D, Hyer JM, Sahara K, Paredes AZ, Mehta R, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020;27:2321-31. [PMID: 32285278 DOI: 10.1245/s10434-020-08452-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Brozzetti S, D’alterio C, Bini S, Antimi J, Rocco B, Fassari A, Lucatelli P, Nardis P, Di Martino M, De Sanctis GM, Corona M, Bagni O, Cortesi E, Bezzi M, Catalano C. Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study. Cancers 2022;14:4422. [DOI: 10.3390/cancers14184422] [Reference Citation Analysis]
2 Papaconstantinou D, Tsilimigras DI, Pawlik TM. . JHC 2022;Volume 9:947-57. [DOI: 10.2147/jhc.s342266] [Reference Citation Analysis]
3 Moazzam Z, Lima HA, Alaimo L, Endo Y, Shaikh CF, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Impact of tumor burden score on timing and patterns of recurrence after curative-intent resection of hepatocellular carcinoma. Surgery 2022:S0039-6060(22)00570-0. [PMID: 36031442 DOI: 10.1016/j.surg.2022.07.019] [Reference Citation Analysis]
4 Zhou Q, Wang X, Li R, Wang C, Wang J, Xie X, Li Y, Li S, Mao X, Liang P. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis. J Gastroenterol 2022. [PMID: 35816221 DOI: 10.1007/s00535-022-01895-3] [Reference Citation Analysis]
5 Shi T, Xu C, Feng Y, Wei Y, Lv H, Zhu Q. Surgical resection versus radiofrequency ablation for early recurrent hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2022. [PMID: 35694799 DOI: 10.1097/MEG.0000000000002393] [Reference Citation Analysis]
6 Xiang C, Xiao Y, Ma Z, Peng Y, Li X, Mao X, Li L. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses. Asia Pac J Clin Oncol 2022. [PMID: 35404506 DOI: 10.1111/ajco.13777] [Reference Citation Analysis]
7 Wang J, Wu D, Sun M, Peng Z, Lin Y, Lin H, Chen J, Long T, Li Z, Xie C, Huang B, Feng S. Deep Segmentation Feature-Based Radiomics Improves Recurrence Prediction of Hepatocellular Carcinoma. BME Frontiers 2022;2022:1-12. [DOI: 10.34133/2022/9793716] [Reference Citation Analysis]
8 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Seehofer D, Sucher R, Denecke T. Resektion und Transplantation bei hepatozellulärem Karzinom und intrahepatischem Cholangiokarzinom. Radiologe. [DOI: 10.1007/s00117-021-00962-9] [Reference Citation Analysis]
10 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
11 Tan Y, Xu Q, Wu Z, Zhang W, Li B, Zhang B, Xu X, Zhang B, Yan K, Song J, Lv T, Yang J, Jiang L, Shi Y, Yang J, Yan L. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Front Oncol 2022;11:783335. [DOI: 10.3389/fonc.2021.783335] [Reference Citation Analysis]
12 Entezari P, Gabr A, Kennedy K, Salem R, Lewandowski RJ. Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes. Semin Intervent Radiol 2021;38:419-24. [PMID: 34629708 DOI: 10.1055/s-0041-1735530] [Reference Citation Analysis]
13 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
14 Chen QF, Dai L, Wu Y, Huang Z, Chen M, Zhao M. Surveillance Strategy for Barcelona Clinic Liver Cancer B Hepatocellular Carcinoma Achieving Complete Response: An Individualized Risk-Based Machine Learning Study. Front Bioeng Biotechnol 2021;9:667641. [PMID: 34540812 DOI: 10.3389/fbioe.2021.667641] [Reference Citation Analysis]
15 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Reference Citation Analysis]
16 Ogawa S, Kubo H, Murayama Y, Kubota T, Yubakami M, Matsumoto T, Yamamoto Y, Morimura R, Ikoma H, Okamoto K, Kamiya M, Urano Y, Otsuji E. Rapid fluorescence imaging of human hepatocellular carcinoma using the β-galactosidase-activatable fluorescence probe SPiDER-βGal. Sci Rep 2021;11:17946. [PMID: 34504174 DOI: 10.1038/s41598-021-97073-1] [Reference Citation Analysis]
17 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg 2021:S0002-9610(21)00471-2. [PMID: 34399978 DOI: 10.1016/j.amjsurg.2021.08.012] [Reference Citation Analysis]
18 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg 2021. [PMID: 34374920 DOI: 10.1007/s13304-021-01147-8] [Reference Citation Analysis]
19 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
20 Yang Y, Xin Y, Ye F, Liu N, Zhang X, Wang Y, Li X, Fan Q, Zhou X, Chen Y. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. Int J Hyperthermia 2021;38:437-46. [PMID: 33724137 DOI: 10.1080/02656736.2020.1849828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tsilimigras DI, Hyer JM, Diaz A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:747. [PMID: 33670174 DOI: 10.3390/cancers13040747] [Reference Citation Analysis]
22 Zheng H, Ma B, Shi Y, Dai Q, Li D, Ren E, Zhu J, Liu J, Chen H, Yin Z, Chu C, Wang X, Liu G. Tumor microenvironment-triggered MoS2@GA-Fe nanoreactor: A self-rolling enhanced chemodynamic therapy and hydrogen sulfide treatment for hepatocellular carcinoma. Chemical Engineering Journal 2021;406:126888. [DOI: 10.1016/j.cej.2020.126888] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 15.0] [Reference Citation Analysis]
23 Moris D, Shaw BI, McElroy L, Barbas AS. Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation. Cancers (Basel) 2020;12:E3372. [PMID: 33202588 DOI: 10.3390/cancers12113372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yang Y, Chen Y, Ye F, Cao X, Xin Y, Wang Y, Lei Y, Li X, Feng D, Zhou X, Fan Q. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol 2021;31:3053-64. [PMID: 33175203 DOI: 10.1007/s00330-020-07460-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Feng LH, Sun HC, Zhu XD, Liu XF, Zhang SZ, Li XL, Li Y, Tang ZY. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur J Surg Oncol 2021;47:681-9. [PMID: 33189491 DOI: 10.1016/j.ejso.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Kuo FY, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH. Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. J Surg Oncol 2021;123:222-35. [PMID: 33084068 DOI: 10.1002/jso.26260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Ding HF, Zhang XF, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Lv Y, Pawlik TM. Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma. Eur J Surg Oncol 2021;47:660-6. [PMID: 33082065 DOI: 10.1016/j.ejso.2020.10.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH, Chen CH. Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. J Surg Oncol 2020;122:1587-94. [PMID: 32815189 DOI: 10.1002/jso.26183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 106] [Article Influence: 13.0] [Reference Citation Analysis]
30 Naar L, Hatzaras I. Liver Resection for Hepatocellular Carcinoma and the Barcelona Clinic Liver Cancer Criteria: Is It Time to Push the Limits? Ann Surg Oncol 2020;27:2122-4. [PMID: 32297086 DOI: 10.1245/s10434-020-08459-w] [Reference Citation Analysis]
31 Tsilimigras DI, Pawlik TM. ASO Author Reflections: Recurrence Patterns and Outcomes After Resection of Hepatocellular Carcinoma Within and Beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020;27:2332-3. [PMID: 32297083 DOI: 10.1245/s10434-020-08455-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]